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Background: Epidemiological evidence suggests that HIV-infected 
individuals are at increased risk of lung cancer, but no data exist 
because large computed tomography (CT) screening trials routinely 
exclude HIV-infected participants.
Methods: From 2006 to 2013, we conducted the world's first lung 
cancer screening trial of 224 HIV-infected current/former smokers to 
assess the CT detection rates of lung cancer. We also used 130 HIV-
infected patients with known lung cancer to determine radiographic 
markers of lung cancer risk using multivariate analysis.
Results: Median age was 48 years with 34 pack-years smoked. 
During 678 person-years, one lung cancer was found on incident 
screening. Besides this lung cancer case, 18 deaths (8%) occurred, 
but none were cancer related. There were no interim diagnoses of 
lung or extrapulmonary cancers. None of the pulmonary nodules 
detected in 48 participants at baseline were diagnosed as cancer 
by study end. The heterogeneity of emphysema across the entire 
lung as measured by CT densitometry was significantly higher in 
 HIV-infected subjects with lung cancer compared with the heteroge-
neity of emphysema in those without HIV (p ≤ 0.01). On multivariate 
regression analysis, increased age, higher smoking pack-years, low 
CD4 nadir, and increased heterogeneity of emphysema on quantita-
tive CT imaging were all significantly associated with lung cancer.
Conclusions: Despite a high rate of active smoking among 
 HIV-infected participants, only one lung cancer was detected in 
678 patient-years. This was probably because of the young age of 
participants suggesting that CT screening of high-risk populations 
should strongly consider advanced age as a critical inclusion crite-
rion. Future screening trials in urban American must also incorporate 
robust measures to ensure HIV patient compliance, adherence, and 
smoking cessation.
Key Words: HIV, Lung cancer, Computed tomography screening, 
Lung cancer screening, High-risk populations.
(J Thorac Oncol. 2014;9: 752–759)
HIV-infected smokers are reported to have a higher rela-tive risk of developing lung cancer compared with that 
in the general population, and lung cancer has emerged as the 
most common and fatal non–AIDS-associated malignancy in 
most western nations.1–10 After controlling for cigarette smok-
ing, the best epidemiological estimates are that HIV infec-
tion increases lung cancer risk by 2.5-fold.11–14 Because lung 
cancer increases markedly with age and duration of smoking, 
lung cancer may become more common and account for even 
more deaths as HIV-infected patients live longer with highly 
active antiretroviral therapy (ART).
The high case fatality rate in HIV-associated lung cancer 
has been shown not to be attributable to HIV-related causes, 
but instead, is primarily attributed to an advanced stage of 
lung cancer presentation in HIV patients.15,16 Late lung cancer 
diagnoses occur even in HIV specialty clinics where frequent 
chest radiographs evaluating opportunistic pulmonary infec-
tions fail to detect lung cancer early.15,17 In fact, approximately 
130 HIV-infected lung cancer patients have presented to our 
institution with more than 80% having late-stage disease.15
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Since the 1990s, computed tomography (CT) has been 
explored as an early detection strategy for lung cancer18–22 
with suggestions that it may allow early-stage diagnosis 
and definitive treatment.23,37 The National Lung Cancer CT 
Screening Trial (NLST) reported a 20% reduction in mor-
tality associated with annual CT screening for older, heavy 
smokers at high risk for lung cancer.24 Given the current 
late stage of presentation of HIV-associated lung cancer, CT 
screening may have profound implications for improving ear-
lier diagnosis of this high-risk group of patients. There are 
no data, however, to support routine lung cancer screening 
in HIV-infected smokers because most CT screening studies, 
including the NLST, excluded their enrollment.
Given that no HIV-infected subjects were enrolled in 
the NLST, the late-stage presentation of HIV-associated lung 
cancer, and the epidemiological evidence suggesting this 
population was at particularly high risk for lung cancer, we 
hypothesized that annual CT screening in HIV-infected smok-
ers may improve early lung cancer detection. From 2006 to 
2013, we initiated a single-armed, prospective, observational 
study assessing the incidence and stage at diagnosis of lung 
cancer among HIV-infected smokers undergoing annual CT 
screening. The primary objective was to determine the prev-
alence and incidence of lung cancer in HIV-infected smok-
ers. Our secondary objectives were to evaluate the feasibility 
and adherence to intensive screening in this population, to 
examine rates of false-positive nodule detection, to determine 
whether CT screening could change the stage distribution of 
HIV-associated cancer to that of an early-stage disease, and 
to determine radiographic markers that may differentiate 
between HIV-infected smokers with and without lung cancer.
PATIENTS AND METHODS
Participants
From January 2006 through May 2013, HIV-infected 
smokers were recruited and followed from HIV outpatient 
clinics throughout Baltimore City and from the AIDS Linked 
to the Intra-Venous Experience cohort at Johns Hopkins.9 The 
study was approved by the Johns Hopkins Institutional Review 
Board, and all subjects provided informed consent. Eligible 
participants were seropositive for HIV by  enzyme-linked 
immunosorbent assay, had no symptoms of a lung malignancy, 
aged 25 years or older, and current or former smokers (quit 
within 15 years) with 20 pack-years of use or more. Exclusion 
criteria included chest CT examination 18 months before 
eligibility, pregnancy, history of lung cancer, active respira-
tory infection, or prior cytotoxic therapy within 6 months. A 
total of 236 participants were registered. Twelve subjects were 
excluded because of a CT scan within 18 months of regis-
tration leaving 224 participants. Forty-nine participants from 
the AIDS Linked to the Intra-Venous Experience study were 
registered from 2010 to 2011 and consented to undergo base-
line and end of study imaging only. All enrolled subjects were 
unselected, and no preference was given toward recruiting 
“healthier” smokers.
Patient navigators tracked all study appointments, includ-
ing contacting subjects before appointments, providing minimal 
financial remuneration for attendance at each visit, and coordi-
nating follow-up study visits with routine clinical care.
Screening
At baseline, smoking habits, general health, occupational, 
and contact data were recorded, and portable spirometry was 
performed. Forced vital capacity and forced expiratory volume 
in 1 second were measured at each CT screening. Participants 
were to have a low-dose helical CT scan at baseline (T0) and 
up to four scans annually (T1–T4). CT screenings were with-
out contrast using a low-dose regimen (120 kVp, 50–200 mA, 
1–5 mm axial reconstruction, 1.1 pitch with collimation of 
64 × 0.6 mm) on a single multidetector scanner (SOMATOM 
64; Siemens Medical Solutions, Erlangen, Germany) with daily 
calibration. Each CT was read independently by two radiolo-
gists with interobserver variability ameliorated through joint 
discussion. Due to previous work in evaluating CT changes 
in HIV patients, we presumed that CT screening would yield 
a high incidence of inflammatory nodules and scarring from 
previous pulmonary infections in HIV-positive patients.25 Our 
protocol thus differed from the current, robust protocols of 
International Early Lung Cancer Action Project (I ELCAP) 26 
and the National Comprehensive Cancer Network (NCCN) for 
CT screening27 in allowing our radiologists to assess noncalci-
fied pulmonary nodules of 4 to 9 mm diameter as suspicious or 
nonsuspicious on an individual basis. Repeat low-dose helical 
CT was recommended at 3 or 6 months for suspicious nodules 
such as enlarging nodules less than 7 mm diameter or those 
with other suspicious changes. For nodules 10 mm in diame-
ter or more or enlarging nodules more than 7 mm in diameter, 
additional diagnostic tests could include CT screening at 3 or 6 
months, fluorodeoxyglucose (FDG)-positron emission tomog-
raphy or Technetium-99m depreotide scintigraphy, or biopsy 
(percutaneous, bronchoscopic, thoracoscopic, or open biopsy).
Vital Status
Participants were contacted semiannually enabling 
updates on health status, contact information, and smoking 
behavior. The social security numbers of those lost to  follow-up 
were cross referenced with the Social Security Death Index to 
ascertain vital status. Cause of death was abstracted from the 
medical record. Data on current CD4 cell count, nadir CD4 
count, HIV viral load, and HIV ART were obtained from 
patients, their health care provider, and from medical records.
CT Densitometry of Screening Participants
CT scans were analyzed for emphysema using 
Pulmonary Workstation 2.0 software (Vida Diagnosis, Iowa 
City, IA). The program determines lung volumes and histo-
gram statistics of all lung pixel attenuation values. Extent 
of emphysema was estimated by quantifying the percent-
age of voxels having an attenuation value lower than −910 
Hounsfield units (HUs). This threshold was chosen empiri-
cally because of the thickness of the CT scans in this study and 
was validated by analyzing several CT scans over a range of 
HUs (from −910 to −1040 HU) in 10-HU increments. All lung 
densitometry measurements were corrected by normalizing 
to the lung air volume being considered. Of the 224 baseline 
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scans available, 117 were able to be used for CT densitometry 
calculations. Two investigators independently performed these 
analyses with any discrepancies resolved by committee.
CT Densitometry of HIV-Infected 
Lung Cancer Patients
From 1989 to 2012 at the Johns Hopkins Hospital, 130 
HIV-infected patients were diagnosed with lung cancer. From 
these patients, 39 had available archived chest CT scan digital 
data that could be analyzed quantitatively.
Statistical Analysis
Comparisons of continuous and dichotomous variables 
between groups were performed with the Student’s t test 
(two-tailed) and χ2 tests, respectively. Multivariable logistic 
regression models estimated odds ratios with 95% confidence 
intervals and were considered significant for p values less than 
0.05. Statistical analyses were performed with STATA soft-
ware (Stata Corporation, College Station, TX).
RESULTS
Participant Characteristics
We recruited 224 asymptomatic HIV smokers for CT 
screening (Table 1). At study entry, the median age was 48 
years, 90% were black, and 58% had a history of injecting 
drugs. Most were current smokers (89%) with a median of 34 
pack-years smoked. Most had previously received ART. These 
224 screened participants were dissimilar demographically to 
130 HIV-associated lung cancer patients previously diagnosed 
at our institution, with the latter being more immunocompro-
mised with higher viral counts and having more obstructive 
lung disease (Supplementary Table 1, Supplementary Digital 
Content 1, http://links.lww.com/JTO/A560). The age distribu-
tion of the screened participants has a bimodal, normal age 
distribution around a median of 48 years old (Supplementary 
Figure 1, Supplementary Digital Content 2, http://links.lww.
com/JTO/A561).
Adherence to Screening
More than 70% of those eligible patients received both 
a baseline CT scan and a CT scan in the final year of the study 
(Fig. 1).The total length of follow-up was 678 patient-years 
with the median length of follow-up being 3.2 years. After 
baseline scanning, 44% of eligible patients received a T1 
scan, 46% had a T2 scan, 68% received a T3 scan, and fully 
71% returned for a final T4 scan (Fig. 1). Participation in each 
annual screening was hindered by regular changes in resi-
dence and frequent alterations in contact information. Of five 
possible scans for all 224 participants, 18 (8%) received only 
one scan, 103 (46%) had two scans, 44 (20%) had three scans, 
39 (17%) had four scans, and 20 (9%) received all five scans.
Screening Results
Forty-eight nodules, 32 at baseline and 16 during inci-
dent screening, were detected during the study period and 
followed (Supplementary Table 2, Supplementary Digital 
Content 1, http://links.lww.com/JTO/A560). The majority of 
the 48 nodules were solid; ground-glass consistency repre-
sented approximately 30%. Only 25% of nodules were larger 
than 1 cm in diameter (Supplementary Table 3, Supplementary 
Digital Content 1, http://links.lww.com/JTO/A560). None of 
these nodules were found to be malignant during subsequent 
examinations. Of the 48 nodules, 38 were judged not to be sus-
picious by the radiologists. These included 14 of 38 thought 
to be caused by chronic inflammation such as from fungal or 
granulomatous disease, whereas 24 of 38 were thought to have 
noninflammatory causes such as active infection, scarring 
TAbLE 1.  Baseline Characteristics of HIV-Infected Individuals 
enrolled in the Lung Cancer Detection by CT Screening Study 
(N = 224)
Characteristics No. of Subjects (%)
Age, median [IQR], yr 48 [44–53]
Sex (M/F) 161/63
Race
  Blacks 201 (90)
  Whites 22 (10)
  Hispanic or Latino 1 (0.5)
Smoking status
  Former 25 (11)
  Current 199 (89)
  Never 0 (0)
Pack-years smoked, median [IQR], yr 34 [31–36]
History of marijuana use 90 (40)
History of cocaine use 65 (29)
IVDU (n = 222) 129 (58)
Hepatitis C (n = 213) 114 (54)
TB skin-test positive (n = 210) 44 (21)
STD (n = 189) 84 (44)
AZT (n = 209) 143 (68)
CD4 nadir, median [IQR], cells per cubic  
millimeter (n = 200)
179 [61–332]
CD4 cell count, median [IQR], cells per cubic 
millimeter (n = 187)
400 [217–568]
Viral load <400 cells per cubic millimeter (n = 207) 123 (59.1)
FEV1, median [IQR],% predicted 85 [70–101]
FVC, median [IQR], % predicted 88 [74–101]
FEV1/FVC, median [IQR], 81 [73–91]
Highest educational level attained (n = 126)
  Middle school 65 (52)
  High school 40 (32)
  College degree 21 (17)
Annual income (n = 87)
  <$8,000 63 (72)
  $8,000 to $14,999 12 (14)
  $15,000 to $24,999 10 (12)
  $25,000 to $49,999 2 (3)
Some subjects had missing demographic data as noted.
IQR, interquartile range; IVDU, intravenous venous drug user; TB, tuberculosis; 
STD, sexually transmitted disease; AZT, azidothymidine; CT, computed tomography; 
FEV1, forced expiratory volume in 1 second; FEV1/FVC, percentage of the vital 
capacity which is expired in the first second of maximal expiration.
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from previous infection, or hamartomas. Ten participants 
with suspicious nodules underwent further CT imaging. Two 
received a positron emission tomography scan, and only one 
had a bronchoscopic biopsy. No participant received surgery 
caused by a false-positive screening.
Although no subject had an interim diagnosis of lung 
cancer, one non–small-cell carcinoma (NSCLC) of advanced 
staged (stage 3B) was detected on incident, first-year screen-
ing after baseline. The baseline screening CT scan of this 
patient was at the time not thought to be clinically significant, 
because the image showed mild hilar adenopathy typical of 
HIV patients. But, by the time of the first annual T1 screening, 
there was clear evidence of interval growth in this patient’s 
hilar mass. The patient elected not to have treatment and died 
4 months after diagnosis. There were 18 other deaths; all due 
to causes other than lung cancer. Sixteen of these patients had 
known CD4 counts at the time of death with 40% (7 of 16) of 
the patients having a CD4 less than 200 cells per cubic mil-
limeter. Of these seven participants, three died of pneumonia 
and respiratory failure, two of cancer (tonsillar and pancre-
atic), and one of encephalitis and renal failure, each.”
Incidental Findings
Of the 224 patients with T0 imaging, 189 partici-
pants (84%) had incidental abnormal intrathoracic findings 
other than suspicious pulmonary nodules. The most often 
observed intrathoracic abnormalities were emphysematous 
changes in 69 (37%), pneumonia in 69 (37%), and CT evi-
dence of coronary artery disease in 58 (31%) participants 
(Supplementary Table 4, Supplementary Digital Content 1, 
http://links.lww.com/JTO/A560). Extrathoracic disease was 
evident in 40% of patients with the majority being renal 
and hepatic abnormalities. There was a low prevalence of 
incidental findings that prompted further investigations in 
the chest and abdomen occurring in 1% and 7%, respec-
tively. Moreover, no extrapulmonary lesions suspicious for 
cancer were identified.
CT Densitometry
Given the high rate of emphysema detected incidentally 
and emphysema’s high predictive value for lung cancer, we 
performed CT densitometry analyses of HIV-infected subjects 
with and without lung cancer. Of the 224 HIV-infected sub-
jects with baseline CT scans, 117 (all without lung cancer) had 
scans suitable for densitometry. Densitometry analyses of the 
117 scans from the CT screening study were compared with 
39 scans from HIV-infected patients with known lung cancer 
diagnosed at our institution. These two groups were dissimilar 
in age, smoking, the use of azidothymidine, and pulmonary 
function tests (Supplementary Table 5, Supplementary Digital 
Content 1, http://links.lww.com/JTO/A560).
To assess the degree of heterogeneity of bilateral 
emphysematous changes in these patients, we measured the 
variability in voxel intensity across both lung fields in those 
with and without cancer. The SD of voxel intensity, corrected 
for lung air volume, was significantly higher in those HIV 
subjects with lung cancer versus those without lung cancer 
(p = 0.0001; Fig. 2).
Because decreased innate immunity has been associ-
ated with emphysema both preclinically and clinically,28,29 
we investigated whether there were differences in the asso-
ciation of nadir CD4 counts and CT densitometry changes 
in  HIV-infected subjects with and without lung cancer. With 
lower nadir CD4 counts in HIV subjects with lung cancer, 
there was a significant increase in emphysematous changes 
by CT densitometric scoring (p < 0.001; Fig. 3). This inverse 
FIgURE 1.  Flow chart of registered and enrolled HIV smokers. Flow diagram of HIV smokers enrolled in the lung cancer screen-
ing study by year of study participation.
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correlation was not observed in HIV subjects without lung 
cancer (p = 0.25). Moreover, because only one HIV patient 
with lung cancer of 39 patients had a nadir CD4 count more 
than 400 cells per cubic millimeter, the threshold of nadir CD4 
may represent a clinical biomarker to identify HIV smokers at 
increased risk for lung cancer.
Using our 117 HIV-positive patients from our screen-
ing cohort and our 39 known HIV-positive lung cancer 
patients, we performed a multivariate logistic regression 
analysis assessing clinical and radiographic risk factors asso-
ciated with lung cancer in HIV-infected patients. Increased 
age, higher pack-years of cigarette smoking, low CD4 count 
nadir, and increased heterogeneity of emphysema on CT 
imaging were all significantly associated with lung cancer in 
HIV patients (Table 2).
DISCUSSION
This observational study is the first to evaluate CT 
screening for lung cancer in HIV smokers. Despite 89% of 
our cohort being active smokers and the epidemiological 
evidence of a twofold increase in lung cancer incidence in 
 HIV-infected versus non–HIV-infected individuals,1–9,30–34 we 
found only one incident cancer during 678 patient-years using 
up to five annual CT screenings. Even with the limitation of a 
small sample size, this is a low rate of lung cancer detection 
despite our appropriate targeting of a community, epidemio-
logically, at high risk for lung cancer.35–41 Although selection 
bias in recruiting “healthier” HIV smokers is a remote pos-
sibility, the more plausible explanation for this low detection 
rate is the cohort’s young median age of 48 years. The normal, 
Gaussian age distribution shows that this recruitment around 
a median age of 48 years old most likely reflects the range of 
ages of HIV-positive patients who sought care at our outpa-
tient clinics and does not suggest selection bias in recruitment. 
We mistakenly hypothesized that the low immunosurveillance 
associated with HIV infection would be the most powerful 
risk factor for lung cancer in our cohort and underestimated 
the significant contribution of advanced age as a risk factor. 
In 2003, when our trial was initially designed, the median 
patient age of all HIV-positive patients in our HIV outpatient 
clinic was 42.4 years. In 2013, with the widespread use of 
ART, the median age of all outpatient HIV-positive patients 
has increased to 52.9 years. Indeed, in most CT screening tri-
als involving  non-HIV subjects, 55 years old is the minimum 
age of eligibility for study participation, and in the original 
I ELCAP CT screening study published in 1999 by Henschke 
et al.36 which showed a 2.7% prevalent lung cancer detection 
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FIgURE 2.  Heterogeneity of emphysema of 39 HIV-infected 
patients with lung cancer and 117 HIV-infected smokers 
without lung cancer as measured by the variability (SD) in 
voxel intensities, corrected for lung air volume. The SD was 
significantly higher in those HIV subjects with lung cancer 
versus those without lung cancer (p = 0.0001).
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FIgURE 3.  Inverse correlation between CD4 counts in 
cells per cubic millimeter and the percentage of voxels with 
attenuation less than −910 HU (corrected for lung air vol-
ume) in 38 HIV-infected patients with lung cancer. Only one 
 HIV-infected individual with lung cancer had a CD4 count 
>400 cells per cubic millimeter.
TAbLE 2.  Adjusted Odds Ratio in 140 HIV Individuals 
(117 HIV-Positive Smokers and 39 HIV-Positive Lung Cancer 
Patients) of Having Lung Cancer Based on Clinical and 
Radiographic Characteristics
Odds Ratio
95% Confidence 
Interval p Value
Clinical characteristics
  Increasing age 1.08 1.01–1.15 0.02
  Increasing pack-years 1.09 1.04–1.15 <0.0001
  Decreasing CD4 nadir 1.006 1.002–1.01 0.006
  Increased SD/TLV 1.23 1.03–1.47 0.02
Logistic regression model includes subjects’ age in years, pack-years cigarette 
smoking history, CD4 nadir counts (continuous), SD/TLV (SD of voxel intensities 
corrected by total bilateral lung air volumes), and the percentage of voxels less than 
−910 Hounsfield units corrected by total lung volume.
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rate, the 1000 participants had a median age of 67 years. 
Prospective cohort studies have also shown a strong associa-
tion between advanced age and increased risk of lung can-
cer in HIV-infected subjects.42 The low rate of HIV-infected 
lung cancer in this trial supports the null hypothesis, and the 
importance of advanced age to lung cancer incidence, even in 
communities at high risk for lung cancer. As more CT screen-
ing programs increasingly develop algorithms to target high-
risk populations of smokers, our negative study suggests that 
the contribution of advanced age as a significant risk factor 
should not be ignored.
We found that noncalcified nodules 4 mm in diameter 
or more were common in smokers who were HIV positive, 
with the majority of them (38 of 48) interpreted as nonsus-
picious by our radiologists due to active infection such as 
tuberculosis and pneumonia, scarring from previous infec-
tion, or granulomatous disease. Only 10 of 48 nodules were 
thought to be suspicious by the radiologists and all partici-
pants with these nodules returned for subsequent imaging. 
These subsequent images all showed definitively that the 
lesions were not malignant, sometimes even showing nod-
ule regression.
More than 80% of the screened cohort had additional 
intrathoracic CT abnormalities, including a third with diffuse 
coronary artery disease, a finding noted previously.43 Similar 
to CT screening trials in non-HIV patients, however, inciden-
tal abnormalities requiring further diagnostic work-up were 
few.44 Such a high rate of additional intrathoracic findings 
is an interesting observation as it begs the question whether 
abnormal CT changes in an HIV-positive and HIV-negative 
patient require similar follow-up, or whether HIV-positive 
patients on ART have medication-induced changes to the lung 
and other organs that are new entities which may raise the 
false-positive rate and cause potential harm to the patient if 
aggressively pursued.
But, the most frequently observed intrathoracic abnor-
malities were emphysematous changes to the lung paren-
chyma. We endeavored to quantify these emphysematous 
abnormalities to assess whether they may prove to differ-
entiate in an even higher risk subpopulation of HIV smok-
ers. We did this by comparing 117 participants from our CT 
screening study with 39 HIV-positive lung cancer patients 
with CT scans who had previously been diagnosed at Johns 
Hopkins. There is a suggested association between bullous 
disease and cannabis usage,45 but the causal link is not estab-
lished.46 In this study, however, there was no difference in 
the cannabis usage between the 117 participants and the 39 
HIV-positive lung cancer patients. Interestingly, there was a 
significant correlation between decreasing nadir CD4 counts 
and increasing degrees of CT-determined emphysema in 
those with lung cancer. Because only one HIV patient with 
lung cancer had a nadir CD4 count more than 400 cells per 
cubic millimeter, our data suggest that a certain threshold 
of nadir CD4 counts for CT screening eligibility may tar-
get those HIV smokers at particularly high risk for emphy-
sema-mediated CT densitometry changes. This could also be 
explained, however, by the possibility that our lung cancer 
patients with HIV, who were older and smoked more, may 
have presented for care later from an immune standpoint, 
with delayed use of ART. However, an increasingly robust 
literature suggests the significant dose–response relation of 
decreasing HIV-induced immunity, often measured by CD4 
counts, and the increasing risk of non–AIDS-defining malig-
nancies.47–49 Finally, our multivariate analysis, between the 
39 patients with lung cancer previously diagnosed at Johns 
Hopkins and those 117 patients without the disease from our 
screening study, also identified low CD4 nadir as a risk factor 
for lung cancer, along with increased age, higher pack-years 
cigarette smoking, and an enhanced heterogeneous pattern 
of emphysema on CT scanning. Injury and inflammation 
are known to be pivotal in the nonuniformity of emphysema 
in the lung,50 and a dysfunctional immune response in HIV 
subjects may have accentuated the upper lobe–predominant 
emphysema observed in HIV subjects.
Despite patient navigators and remuneration for contin-
ued participation, this study is limited by few eligible subjects 
returning for all five scans. Longitudinal engagement in regu-
lar HIV care in U.S. urban settings also is a limitation to effec-
tive antiretroviral treatment.51 A recent report of 22,984 adult 
HIV outpatients receiving care in the United States between 
2001 to 2009 indicated that only 20.4% of HIV outpatients 
were retained as patients on a continual basis without inter-
ruption or loss to follow-up.52 Urban HIV cohorts with a high 
prevalence of polysubstance abuse are especially vulnerable 
to poor compliance and follow-up rates.53,54 Many of our par-
ticipants returned for a final CT screening at study’s end with 
more than 70% of eligible HIV subjects completing at least a 
baseline and final CT scan. This suggests that only 14% of our 
original cohort were truly lost to follow-up, and the majority 
of participants were merely grossly noncompliant.
Because only one lung cancer was detected, we were 
unable to investigate the secondary endpoint concern-
ing whether CT screening changes the stage distribution of 
NSCLC in screened HIV patients versus historic controls. 
The NLST suggests that stage distribution may change in 
non-HIV individuals, but the aggressiveness of NSCLC in the 
 HIV-infected patient makes this an open question.
Given the results of this pilot screening study, consid-
erable thought must be given concerning the execution of any 
large screening study in this high-risk population especially 
given the many other factors that could make a case against 
lung cancer screening in such persons; such as “over diag-
nosis bias,”55competing mortality over a course of screening, 
more aggressive cancer types, faster interval progression of 
cancers, and the personal anxiety, financial burden, and the 
morbidity because of the work-up of false-positive tests. At 
the very minimum, we believe that until the median age of 
HIV smokers increases, the rate of detection by helical CT 
of  HIV-associated lung cancers will remain low. Advanced 
age and length of exposure to cigarette smoking are strong 
risk factors for lung cancer, and most CT screening studies 
use age older than 55 years as an important eligibility crite-
rion. Our identification of biologic and radiographic markers 
in HIV smokers to define an even higher subpopulation of 
high-risk individuals may allow algorithms to determine lung 
cancer risk more effectively, individualize the frequency of 
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subsequent scans, reduce false positives, and limit the costs 
of future lung cancer screening trials. Given the high rate 
of active smokers in an HIV community and the epidemio-
logical data, as the median age of HIV-infected individuals 
surpasses 55 years in the United States, perhaps a far larger 
study enrolling older HIV-positive smokers may answer 
some of the initial questions we raised here. However, for 
such a study to be feasible in an urban American HIV cohort 
plagued by polysubstance abuse, considerable measures to 
ensure patient compliance, adherence, and smoking cessa-
tion must also ensue.
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